Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MTHFD1L CRISPR/Cas9 KO Plasmid (h): sc-417762
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MTHFD1L CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MTHFD1L genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MTHFD1L Antibody (D-7): sc-515706
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MTHFD1L CRISPR/Cas9 KO Plasmid (h) | sc-417762 | 20 µg | $397.00 |
Overview
MTHFD1L encodes a mitochondrial folate-dependent enzyme that supports one-carbon metabolism by generating formate and related one-carbon units used to sustain cytosolic folate cycles. This activity links mitochondrial serine/glycine catabolism to nucleotide biosynthesis, methylation capacity, and redox balance, influencing DNA replication and epigenetic regulation. Altered MTHFD1L function has been associated with metabolic remodeling and proliferative phenotypes observed across multiple disease contexts, including cancer-related one-carbon pathway rewiring. As a result, MTHFD1L is frequently studied in the context of folate metabolism, mitochondrial function, and genome stability under nutrient or oxidative stress.
MTHFD1L CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MTHFD1L gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MTHFD1L together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MTHFD1L open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MTHFD1L protein expression.
This CRISPR knockout system enables efficient generation of MTHFD1L-deficient cell models for investigation of MTHFD1L signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MTHFD1L exon(s) critical for MTHFD1L function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MTHFD1L genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MTHFD1L CRISPR/Cas9 KO Plasmid (h) and MTHFD1L CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MTHFD1L locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MTHFD1L HDR Plasmid (h) and MTHFD1L HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MTHFD1L homology arms to support homology-directed repair at defined MTHFD1L target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.